TOP TEN perturbations for 534_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 534_s_at
Selected probe(set): 204437_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 534_s_at (204437_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic)

Relative Expression (log2-ratio):6.733329
Number of Samples:2 / 5
Experimental expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium.
Control expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant mixed Mullerian tumor of the endometrium.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)

Relative Expression (log2-ratio):5.794471
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (endometrioid carcinoma; metastatic)

Relative Expression (log2-ratio):5.7276506
Number of Samples:2 / 20
Experimental expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium.
Control expO endometrial cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the endometrium.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):5.655658
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (serous cystadenocarcinoma)

Relative Expression (log2-ratio):-5.56987
Number of Samples:44 / 71
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (serous cystadenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)

Relative Expression (log2-ratio):5.4314957
Number of Samples:2 / 6
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):5.3780966
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)

Relative Expression (log2-ratio):-5.3746758
Number of Samples:6 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.
Control expO ovary cancer study 1 (carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS).

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):5.3446016
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

nephroblastoma study 2 / normal kidney tissue

Relative Expression (log2-ratio):-5.213621
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue
Normal adult kidney tissue samples.